Paper
German-Canadian family (family A) with parkinsonism, amyotrophy, and dementia — Longitudinal observations

https://doi.org/10.1016/S1353-8020(97)00013-8Get rights and content

Abstract

Etiology of Parkinson's disease (PD), amyotrophy lateral sclerosis (ALS), and Alzheimer's disease (AD) remains uncertain. Environmental factors probably play a role, but genetic influences may predispose certain individuals to develop each of these major neurodegenerative disorders.

We describe our longitudinal observations concerning a Canadian family traced to Northern Germany. Autosornal dominant inheritance has been established. Affected members present with L-dopa responsive parkinsonism and amyotrophy. In the German portion of the family some individuals displayed only dementia or focal dystonia. Linkage analysis studies performed with polymorphic markers associated with 13 candidate genes provided no significant evidence for linkage with any of the genes examined. Positron emission tomography with [18F]-6-fluoro-L-dopa (FD) and [su11C]-raclopride (raclopride) of one affected subject revealed reduced striatal FD uptake particularly in putamen, and an increased raclopride striatum/background ratio. Postmortem levels of dopamine and its metabolites were greatly reduced in caudate and putamen of two patients. There was substantial neuronal loss in the substantia nigra and the presence of abundant eosinophilic granules (different than Lewy bodies) in surviving neurons. One of them also showed mild loss of anterior horn cells, while another showed abundant senile plaques and some neurofibrillary tangles in distribution and intensity typical of mild to moderate AD.

Our report further describes this unique family with a combination of clinical features of PD, ALS, and AD. By studying kindreds like this we may learn more about the pathophysiology of sporadic forms of PD, ALS, or even AD.

References (96)

  • R.J. Martilla et al.

    Parkinson's disease in a nationwide twin cohort

    Neurology

    (1988)
  • W.G. Johnson et al.

    Twin studies and the genetics of Parkinson's disease—a reappraisal

    Mov. Disord.

    (1990)
  • P. Vieregge et al.

    Parkinson's disease in twins

    Neurology

    (1992)
  • D.J. Burn et al.

    Parkinson's disease in twins studied with BF-dopaand positron emission tomography

    Neurology

    (1992)
  • V.A. Holthoff et al.

    Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits

    Ann. Neurol.

    (1994)
  • F. Tison et al.

    Dementia in Parkinson's disease: a population-based study in ambulatory and institutionalized individuals

    Neurology

    (1995)
  • D. Majoor-Krakauer et al.

    Familial aggregation of amyotrophic lateral sclerosis, dementia, and Parkinson's disease: evidence of shared genetic susceptibility

    Neurology

    (1994)
  • A.M. Murray et al.

    Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism

    Ann. Neurol.

    (1995)
  • K.P. Bhatia et al.

    Familial parkinsonism with depression: a clinicopathological study

    Ann. Neural.

    (1993)
  • P. Vieregge

    Genetic factors in the etiology of idiopathic Parkinson's disease

    J. Neural Transm. [P-D Sect.]

    (1994)
  • J. Feamley et al.

    Pathology of Parkinson's disease

  • J. Jankovic

    Parkinsonism-plus syndromes

    Mov. Disord.

    (1989)
  • Z.K. Wszolek et al.

    Hereditärer morbus Parkinson: bericht über drei familien mit autosomal-dominantem erbgang

    Nervenarzt

    (1993)
  • F.J.G. Vingerhoets et al.

    Reproducibility of fluorine- 18-6-fluorodopa positron emission tomography in normal human subjects

    J. Nucl. Med.

    (1994)
  • D.L. Bailey et al.

    A convolution-subtraction scatter correction method for 3D PET

    Phys. Med. Biol.

    (1994)
  • P.E. Kinahan et al.

    Analytic 3D image reconstruction using all detected events

    IEEE Trans. Nucl. Sci.

    (1989)
  • C.C. Li et al.

    A simple method of estimating the segregation ratio under complete ascertainment

    Am. J. Hum. Genet.

    (1968)
  • M.A. Anderson et al.

    Use of cyclosporine A in establishing human Epstein-Barr-virus-transformed lymphoblastoid cell lines

    In Vitro Cell Dev. Biol.

    (1984)
  • J.L. Weber et al.

    Abundant class of human DNA polymoprhisms which can be typed using the polymerase chain reaction

    Am. J. Hum. Genet.

    (1989)
  • T. Gasser et al.

    Linkage studies in autosomal dominant Parkinsonism: evaluation of seven candidate genes

    Ann. Neurol.

    (1994)
  • G.M. Lathrop et al.

    Strategies for multilocus analysis in humans

  • G. Gyapay et al.

    The 1993–1994 Genethon human linkage map

    Nature Genet.

    (1994)
  • M.H. Polymeropoulos et al.

    Mapping of a gene for Parkinson's disease to chromosome 4g21-q23

    Science

    (1996)
  • W. Beyerley et al.

    VNTR polymorphism for the human dopamine transporter gene (DAT1)

    Hum. Molec. Genetics

    (1993)
  • A. Voltz et al.

    Report of the Second International Workshop on human chromosome 6

    Genomics

    (1994)
  • H. Ichinose et al.

    Hereditary progressive dystonia with marked diurnal fluctuations caused by mutations in the GTP cyclohydrolase 1 gene

    Nature Genet.

    (1994)
  • R. Sherrington et al.

    Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

    Nature

    (1995)
  • T.G. Nygaard et al.

    Linkage mapping of dopa-responsive dystonia (DRD) to chromosome 14q

    Nature Genet.

    (1993)
  • G.D. Schellenberg et al.

    Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14

    Science

    (1992)
  • P.J. Tuite et al.

    Doparesponsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion

    Ann. Neurol.

    (1995)
  • T. Yamada et al.

    Histological and biochemical pathlolgy in a family with autosomal dominant parkinsonism and dementia

    Neurol. Psychiat. Brain Res.

    (1993)
  • P.L. McGeer et al.

    Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

    Neurology

    (1988)
  • P.L. McGeer et al.

    Expression of the histocompatibility glycoprotein HLA-DR in neurological disease

    Acta Neuropathol.

    (1988)
  • T. Yamada et al.

    Relationship of complement-activated oligodendrocytes to reactive microglia and neuronal pathology in neurodegenerative disease

    Dementia

    (1991)
  • A.M. Hakim et al.

    Dementia in Parkinson's disease: a neuropathologic study

    Neurology

    (1979)
  • F. Boller et al.

    Parkinson's disease, dementia, and Alzheimer's disease: clinicopathological correlations

    Ann Neurol

    (1980)
  • P.J. Whitehouse et al.

    Basal forebrain neurons in the dementia of Parkinson's disease

    Ann. Neurol.

    (1983)
  • P. Gaspar et al.

    Dementia in idiopathic Parkinson's disease. A neuropathological study of 32 cases

    Acta Neuropathol.

    (1984)
  • Cited by (69)

    • Towards a biological diagnosis of PD

      2024, Parkinsonism and Related Disorders
    • PET Molecular Imaging in Familial Parkinson's Disease

      2018, International Review of Neurobiology
      Citation Excerpt :

      Other series have shown a variety of pathological changes, most commonly neuronal loss and gliosis in the substantia nigra and variable distributions of Lewy bodies and/or neurites (Funayama et al., 2005; Gaig & Tolosa, 2009; Hasegawa et al., 2009; Khan, Jain, et al., 2005; Martí-Massó et al., 2009; Puschmann et al., 2012; Wszolek et al., 2004). Based on large family studies including patients with different LRRK2 mutations, the distribution of PET dopaminergic tracer changes in LRRK2-PD is similar to iPD (Adams et al., 2005; Hasegawa et al., 2009; Sossi et al., 2010; Wszolek et al., 1995, 1997). Patients show a posterior-to-anterior gradient of dopamine deficiency contralateral to the clinically more affected side, with earlier and more severe dopaminergic dysfunction of the posterior putamen relative to caudate.

    • Clinical heterogeneity of LRRK2 p.I2012T mutation

      2016, Parkinsonism and Related Disorders
      Citation Excerpt :

      The majority of previously described LRRK2 mutations are either p.R1441C/G/H on the Ras of complex proteins (ROC) domain or p.G2019S on the kinase domain, and have clinical phenotypes of typical late-onset levodopa-responsive PD. However, a small number of reported cases show atypical features, such as dementia, dystonia, amyotrophy, and progressive supranuclear palsy [19,20]. Notably, p.G2019S mutation was detected in a 79-year-old man with a clinical and neuropathological diagnosis of frontotemporal dementia [21].

    • Genotype-Phenotype Correlations in Parkinson Disease

      2015, Movement Disorders: Genetics and Models: Second Edition
    • TDP-43 pathology in a patient carrying G2019S LRRK2mutation and a novel p.Q124E MAPT

      2013, Neurobiology of Aging
      Citation Excerpt :

      Rajput et al reported a case with slow, progressive, non–levodopa-responsive parkinsonism and tau-positive NFTs resembling the neuropathology of PSP (Rajput et al., 2006), Giasson et al and Gaig et al each reported a case with classical tremor-dominant parkinsonism and pure nigral degeneration (Gaig et al., 2008; Giasson et al., 2006), and, Dachsel et al reported a case with dementia and tremor and pathology consisted of FTLD with ubiquitinated neuronal inclusions (FTLD-U) (Dachsel et al., 2007). On the other hand, pleomorphic pathologies including α-synuclein, tau, and ubiquitin seem to be more commonly associated with other pathogenic LRRK2 mutations (Hasegawa and Kowa, 1997; Hasegawa et al., 2009; Santpere and Ferrer, 2009; Wszolek et al., 1997, 2004; Zimprich et al., 2004). We report a case with LRRK2 G2019S mutation clinically diagnosed as Parkinson's disease, with good levodopa response, in which neuropathological analysis revealed nigral degeneration with an absence of Lewy bodies, Alzheimer-type tau, and TDP-43 pathologies.

    View all citing articles on Scopus
    View full text